1. Academic Validation
  2. Discovery of 2,4-1 H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors

Discovery of 2,4-1 H-Imidazole Carboxamides as Potent and Selective TAK1 Inhibitors

  • ACS Med Chem Lett. 2021 Mar 3;12(4):555-562. doi: 10.1021/acsmedchemlett.0c00547.
Johan J N Veerman 1 Yorik B Bruseker 2 Eddy Damen 2 Erik H Heijne 2 Wendy van Bruggen 2 Koen F W Hekking 2 Rob Winkel 2 Christopher D Hupp 3 Anthony D Keefe 3 Julie Liu 4 Heather A Thomson 3 Ying Zhang 3 John W Cuozzo 3 Andrew J McRiner 3 Mark J Mulvihill 5 Peter van Rijnsbergen 2 Birgit Zech 6 Louis M Renzetti 7 Lee Babiss 8 Gerhard Müller 6
Affiliations

Affiliations

  • 1 ZoBio BV, J.H. Oortweg 19, 2333 CH Leiden, The Netherlands.
  • 2 Mercachem BV, Department of Medicinal Chemistry, Kerkenbos 1013, 6546 BB Nijmegen, The Netherlands.
  • 3 X-Chem, Inc., 100 Beaver Street, Waltham, Massachusetts 02453, United States.
  • 4 Civetta Therapeutics, 10 Wilson Road, Cambridge, Massachusetts 02138, United States.
  • 5 HiberCell Inc., New York, New York 10019, United States.
  • 6 AnavoTherapeutics BV, J.H. Oortweg 19, 2333 CH Leiden, The Netherlands.
  • 7 Bridge Medicines LLC, New York, New York 10017, United States.
  • 8 Wilmington, North Carolina 28405, United States.
Abstract

Herein we report the discovery of 2,4-1H-imidazole carboxamides as novel, biochemically potent, and kinome selective inhibitors of transforming growth factor β-activated kinase 1 (TAK1). The target was subjected to a DNA-encoded chemical library (DECL) screen. After hit analysis a cluster of compounds was identified, which was based on a central pyrrole-2,4-1H-dicarboxamide scaffold, showing remarkable kinome selectivity. A scaffold-hop to the corresponding imidazole resulted in increased biochemical potency. Next, X-ray crystallography revealed a distinct binding mode compared to other TAK1 inhibitors. A benzylamide was found in a perpendicular orientation with respect to the core hinge-binding imidazole. Additionally, an unusual amide flip was observed in the kinase hinge region. Using structure-based drug design (SBDD), key substitutions at the pyrrolidine amide and the glycine resulted in a significant increase in biochemical potency.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-132172
    98.22%, TAK1 Inhibitor